Table 2.
Mechanisms of liver damage
|
Treatments
|
Caution
|
Ref.
|
Hepatocellular injury | Hepatoprotective, anti-inflammatory, and jaundice-reducing agents | Preventive administration is not recommended | [109,111,112] |
Cytokine storm syndrome | Continuous renal replacement therapy. IL-1 inhibitor, IL-6 inhibitor, TNF inhibitor | IL-1 or IL-6 inhibitors could reduce inflammation; however, they have a potential to cause DILI and worsen clinical conditions | [109,139,140] |
DILI | Prompt discontinuation or reduction of doses of suspected triggers. Medication reconciliation is important. Discontinue all non-vital therapy, redundant types/doses, modify course duration | Requires a trade-off between therapeutic effects and side effects | [109] |
Reactivation of pre-existing liver disease | Continue treatment for hepatitis B and hepatitis C if already on treatment | Difficulty distinguishing between new-onset liver injury and reactivation of pre-existing liver disease | [16,109] |
Hypoxic hepatitis | Circulation and respiratory support | Higher PEEP, which may be needed to improve oxygenation, may affect cardiac output, decreasing hepatic arterial flow, thus enhancing arterial dysfunction | [139,140] |
DILI: Drug-induced liver injury; IL: Interleukin; PEEP: Positive end-expiratory pressure; TNF: Tumor necrosis factor alpha.